Vivodyne CEO drops a critical insight on why CAR-T therapies dominate in vitro but fail in vivo for solid tumors.
In controlled lab conditions (2D cultures, ideal nutrient delivery), engineered CAR-T cells obliterate tumor cells with near-perfect efficacy. The problem? Solid tumors in patients create hostile microenvironments:
🔬 Vascular barriers: CAR-T cells circulate through blood vessels but can't penetrate dense tumor stroma
🔬 Immunosuppressive zones: Hypoxia, TGF-β, and regulatory T cells shut down CAR-T function
🔬 Antigen heterogeneity: Tumor cells downregulate target antigens, evading recognition
This extravasation failure is why liquid cancers (leukemia, lymphoma) respond to CAR-T while pancreatic/glioblastoma trials crash. The engineering challenge isn't just receptor design—it's trafficking, persistence, and navigating 3D tumor architecture.
Vivodyne is likely building organ-on-chip models to simulate these in vivo barriers during preclinical testing, closing the gap between petri dish fantasy and clinical reality.
In controlled lab conditions (2D cultures, ideal nutrient delivery), engineered CAR-T cells obliterate tumor cells with near-perfect efficacy. The problem? Solid tumors in patients create hostile microenvironments:
🔬 Vascular barriers: CAR-T cells circulate through blood vessels but can't penetrate dense tumor stroma
🔬 Immunosuppressive zones: Hypoxia, TGF-β, and regulatory T cells shut down CAR-T function
🔬 Antigen heterogeneity: Tumor cells downregulate target antigens, evading recognition
This extravasation failure is why liquid cancers (leukemia, lymphoma) respond to CAR-T while pancreatic/glioblastoma trials crash. The engineering challenge isn't just receptor design—it's trafficking, persistence, and navigating 3D tumor architecture.
Vivodyne is likely building organ-on-chip models to simulate these in vivo barriers during preclinical testing, closing the gap between petri dish fantasy and clinical reality.